The Medical Letter on Drugs and Therapeutics
FROM
ISSUE1503
ISSUE1503
September 12, 2016
Daclizumab (Zinbryta) for Multiple Sclerosis
Subscribers: Log in to read full article. Not a subscriber? Subscribe or purchase article. |
Daclizumab (Zinbryta) for Multiple Sclerosis
September 12, 2016 (Issue: 1503)
The FDA has approved daclizumab (Zinbryta – Biogen/Abbvie), an interleukin-2 (IL-2) receptor blocking
monoclonal antibody, for treatment of adults with
relapsing forms of multiple sclerosis (MS). It is the
first subcutaneously injected...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.